Researchers reported on the severity of COVID-19 outcomes in patients with psoriatic disease, using data from the WARCOV study.
The long-term persistence of various biologic agents in treating psoriasis and psoriatic arthritis are investigated.
A team of researchers performed an integrated safety analysis from 4 clinical trials among patients with psoriatic arthritis to assess the safety profile of ixekizumab.
Authors of a systematic review compared the efficacy and safety of systemic therapies in the treatment of manifestations of active psoriatic arthritis.
Lloyd S. Miller, MD, PhD, writes about understanding the overlapping immune pathways between psoriasis and psoriatic arthritis that may be useful to develop treatment plans for patients with these conditions.
Researchers sought to determine the prevalence of sleep disturbances among patients with psoriatic arthritis vs those with psoriasis and healthy individuals.
Investigators sought to determine whether cTnI and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) were associated with carotid plaque burden and CV events independent of the Framingham Risk Score (FRS).
Presenting at the 2022 AAN Annual Meeting, researchers evaluated a case of 48-year-old woman who developed atypical optic neuritis induced by golimuab treatment.
Rheumatologist Steven Vlad, MD, and dermatologist David Rosmarin, MD, discuss the various aspects of telemedicine in relation to providing care to patients with psoriasis and psoriatic arthritis during and after the COVID-19 pandemic.
Researchers studied the link between clinical examination and ultrasound synovitis in DMARD-naive patients with early psoriatic arthritis.